Skip to main content Accessibility help

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

  • Piotr Ozierański (a1), Martin McKee (a2) and Lawrence King (a3)


This paper aims to fill in the gap in research on the effect of pharmaceutical lobbying on drug reimbursement policy, particularly in Poland, a post-communist country. To this end, we conducted in-depth, semi-structured, anonymous, elite interviews in Poland, supplemented by a review of legislation, policy documents, official reports and press articles, as well as observations. Overall, 109 representatives of stakeholders involved in reimbursement policy were interviewed. We identified two key lobbying methods: informal persuasion and third-party endorsements. These methods are coupled with two supplementary ones: lobbying through parliament and ministries, as well as diplomatic pressure. Pharmaceutical lobbying methods in Poland clearly resemble those used in other European countries. What is notable about the Polish case is extensive reliance on informal lobbying and diplomatic pressure.


Corresponding author

Correspondence to: Dr. Lawrence King, Department of Sociology, University of Cambridge, Free School Lane, Cambridge, CB2 3RQ, UK. Email:


Hide All
Abraham, J. (2002), ‘The pharmaceutical industry as a political player’, The Lancet, 360: 14981502.
Abraham, J. (2009), ‘Partial progress: governing the pharmaceutical industry and the NHS, 1948–2008’, Journal of Health Politics, Policy and Law, 34: 931977.
Abraham, J. (2010), ‘Pharmaceuticalization of society in context: theoretical, empirical and health dimensions’, Sociology, 44: 603622.
Abraham, J.Lewis, G. (2000), Regulating medicines in Europe: competition, expertise and public health, London: Routledge.
American Sociological Association (1999), Code of ethics and policies and procedures of the ASA Committee of Professional Ethics, Washington, DC: American Sociological Association.
Angell, M. (2005), The truth about drug companies. How they deceive us and what to do about it?, New York: Random House.
Baggot, R., Allsop, J.Jones, K. (2005), Speaking for patients and carers. Health consumer groups and the policy process, Basingstoke: Palgrave.
Berrett, A., Roques, T., Small, M.Smith, R. D. (2006), ‘How much will Herceptin really cost?’, British Medical Journal, 333: 1118.
Buckwell, C. (2008), ‘Should the drug industry work with key opinion leaders? Yes’, British Medical Journal, 336: 1404.
Burson-Marsteller, (2010), Acceso a los medicamentos, principal prioridad de la industria farmacéutica, 10 September, [6 November 2010].
Choukroun, B. (2010), ‘The swine flu epidemic: compared analysis of the epidemic media coverage by French and British media’, Lexis Nexis Analytics, October, [6 November 2010].
Cohen, D.Carter, P. (2010), ‘Conflicts of interest. WHO and the pandemic flu “conspiracies” ’, British Medical Journal, 340: c2912.
Conrad, P. (2007), The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders, Baltimore, M.D.: Johns Hopkins University Press.
Fava, G. A. (2008), ‘Should the drug industry work with key opinion leaders? No’, British Medical Journal, 336: 1405.
Ferner, R. E.McDowell, S. E. (2006), ‘How NICE may be outflanked’, British Medical Journal, 332: 12681271.
García-Sempere, A.Artell, J. J. (2005), ‘Organización, funcionamiento y expectativas de las organizaciones representativas de pacientes. Encuesta a informadores clave’, Gaceta Sanitaria, 19(2): 120126.
Geertz, C. (1973), ‘Thick description: toward an interpretive theory of culture’, in C. Geertz (ed.), The Interpretation of Cultures: Selected Essays, New York: Basic Books, 330.
Grant, W. (2000), Pressure Groups and British Politics, London: MacMillan.
Hague, R., Harrop, M. (1992), Comparative government and politics: an introduction (3rd revised edition), Basingstoke: Macmillan.
Health Committee (2005), The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–2005, London: Stationery Office.
Hemminki, E., Toiviainen, H. K.Vuorenkoski, L. (2010), ‘Co-operation between patient organisations and the drug industry in Finland’, Social Science and Medicine, 70(8): 11711175.
Herxheimer, A. (2003), ‘Relationships between the pharmaceutical industry and patients’ organisations’, British Medical Journal, 326: 12081210.
Hood, C. (2011), The blame game: spin, bureaucracy and self-preservation in government, Princeton, N.J.: Princeton University Press.
IMS Health and Rynek Zdrowia (2010), ‘Polska w czołówce rynków wschodzących w farmacji’. Rynek Zdrowia, 21 April,,17503,6.html [14 September 2010].
Jakubiak, L. (2009a), ‘Podawanie paliwizumabu wcześniakom: nie ma zgodności co do oceny skuteczności’, Rynek Zdrowia, 16 October,,11816,6.html [15 September 2010].
Jakubiak, L. (2009b), ‘Rynek leków kreuje korupcjogenne zachowania, trzeba więc z tym walczyć’, Rynek Zdrowia, 12 December,,13764,2,1.html [10 November 2010].
Jones, K. (2008), ‘In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK’, Sociology of Health and Illness, 30(6): 929943.
Kent, A. (2007), ‘Should patient groups accept money from drug companies? Yes’, British Medical Journal, 334: 934.
Kopřivová, H. (2007), ‘Postavení farmaceutických firem v českém zdravotním systemu’, Diploma Thesis. Masarykova univerzita, Brno, [6 November 2010].
Kvale, S. (1996), InterViews. An introduction to qualitative research interviewing, London, Thousand Oaks, New Delhi: SAGE Publications.
Łapiński, M. (2005), Walka z sitwą, Warszawa: Offsetowa Drukarnia Wydawnicza.
Ledeneva, A. V. (2006), How Russia really works? The informal practices that shaped Post-Soviet politics and business, Ithaca, NY: Cornell University Press.
Malinowski, B. (2002), Argonauts of the Western Pacific: An account of native enterprise and adventure in The Archipelagoes of Melanesian New Guinea, London and New York: Routledge.
Meyer, G. (ed.) (2006) Formal institutions and informal politics in Central and Eastern Europe. Hungary, Poland, Russia and Ukraine, Opladen and Farmington Hills: Barbara Budrich Publishers.
Ministerstwo Zdrowia (2004), Polityka lekowa państwa 2004–2008, Warszawa: Ministerstwo Zdrowia.
Ministerstwo Zdrowia (2005), Strategia rozwoju ochrony zdrowia w Polce na lata 2007–13. Dokument przyjęty przez RM w dniu 21 czerwca 2005 r, Warszawa: Ministerstwo Zdrowia.
Mintzes, B. (2007), ‘Should patient groups accept money from drug companies? No.’, British Medical Journal, 334: 935. (2007), ‘SN: Deszczyński ma być przeproszony za tekst “Leki za miliony dolarów” ’., 13 April,;deszczynski;ma;byc;przeproszony;za;tekst;leki;za;miliony;dolarow,20,0,235796.html [24 September 2010].
Moynihan, R. (2003), ‘Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement’, British Medical Journal, 326: 11891192.
Moynihan, R. (2008), ‘Key opinion leaders. Independent experts or drug representatives in disguise?’, British Medical Journal, 336: 14021403.
Moynihan, R., Heath, I.Henry, D. (2003), ‘Selling sickness: the pharmaceutical industry and disease mongering’, British Medical Journal, 324: 886891.
Nicoll, A.McKee, M. (2010), ‘Moderate pandemic, not many dead – learning the right lessons in Europe from the 2009 pandemic’, European Journal of Public Health, 20(5): 486488.
Najwyższa Izba Kontroli (2004), Informacja o wynikach kontroli funkcjonowania systemu tworzenia wykazu leków refundowanych.
Najwyższa Izba Kontroli (2007), Wystąpienie pokontrolne – Samodzielny Publicznym Szpitalu Klinicznym nr 5 Śląskiego Uniwersytetu Medycznego.
Najwyższa Izba Kontroli (2009), Wystąpienie pokontrolne – Zespół Opieki Zdrowotnej w Końskich (ZOZ).
Narodowy Fundusz Zdrowia (2006), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2005 rok, Warszawa: Narodowy Fundusz Zdrowia.
Narodowy Fundusz Zdrowia (2007), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2006 rok, Warszawa: Narodowy Fundusz Zdrowia.
Narodowy Fundusz Zdrowia (2008), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2007 rok, Warszawa: Narodowy Fundusz Zdrowia.
Narodowy Fundusz Zdrowia (2009), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2008 rok, Warszawa: Narodowy Fundusz Zdrowia.
Narodowy Fundusz Zdrowia (2010a), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2009 rok, Warszawa: Narodowy Fundusz Zdrowia.
Narodowy Fundusz Zdrowia (2010b), Zmiana planu finansowego Narodowego Funduszu Zdrowia na 2010 r. zatwierdzona przez Ministra Zdrowia w porozumieniu z Ministrem Finansów w dniu 6 lipca 2010 r, Warszawa: Narodowy Fundusz Zdrowia.
OECD (2011), Consumer prices (MEI): consumer prices – annual inflation, [22 April 2011].
Oldani, M. J. (2004), ‘Thick prescriptions: toward an interpretation of pharmaceutical sales practices’, Medical Anthropology Quarterly, 18: 325356.
Parliamentary Assembly of the Council of Europe (2010), Report, recommendation and resolution 24/06/2010. The handling of the H1N1 Pandemic: more transparency Needed, Strasbourg: Parliamentary Assembly of the Council of Europe.
Payet, M. (2010), ‘Swine flu experts under the influence of laboratories. Le Parisien explores pharma links to WHO and French government,’ (Translated by Carolyn Dunning) Le Parisien, 26 January, [5 November 2010].
Peräkylä, A. (1997), ‘Reliability and validity in research based on tapes and transcripts’, in D. Silverman (ed.), Qualitative Research. Theory, Methods and Practice, London, Thousand Oaks, New Delhi: Sage Publications, 201220.
Procedura (2009), Procedura przyjmowania klientów zewnętrznych, Warszawa: Ministerstwo Zdrowia.
Rynek Zdrowia (2010), ‘Coraz dłuższa kolejka chętnych do poprawiania projektu ustawy refundacyjnej’, 18 October,,102783,6.html [10 November 2010].
Silverman, D. (1993), Interpreting qualitative data. Methods for analysing talk, text and interaction, London: Sage Publications.
Sismondo, S. (2008), ‘How pharmaceutical industry funding affects trial outcomes: causal structures and responses’, Social Science & Medicine, 66: 19091914.
Solska, J. (2009), ‘Zakładnicy’, Polityka 21 February.
Spielmans, G. I.Parry, P. I. (2010), ‘From evidence-based medicine to marketing-based medicine: evidence from internal industry documents’, Journal of Bioethical Inquiry, 7(1): 1329.
Strauss, A. L. (2001), Qualitative analysis for social scientists, Cambridge: Cambridge University Press.
The Lancet (2005), ‘Herceptin and early breast cancer: a moment for caution’, The Lancet, 366(9498): 1673.
Tiedemann, A. (2009), EU market access teams: new instruments to tackle non-tariff barriers to trade, Bruges: College of Europe.
Traufetter, G. (2009), ‘German government flu expert advising pharma “lobby group” ’, Spiegel Online International, 28 October,,1518,657910,00.html [5 November 2010].
Ustawa (2009), Ustawa z dnia 6 listopada 2008 r. o konsultantach w ochronie zdrowia, Dz.U. Dz.U. 2009 nr 52 poz. 419.
Vuorenkoski, L., Toiviainen, H.Hemminki, E. (2003), ‘Drug reimbursement in Finland: the case of explicit prioritising in special categories’, Health Policy, 66(2): 169177.
Wilson, P. M., Booth, A. M., Eastwood, A.Watt, I. S. (2008), Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage’, Journal of the Royal Society of Medicine, 101(3): 125132.
Zarzycki, T., (2010), ‘Firmy farmaceutyczne muszą dostosować się do zmian prawnych’, Rynek Zdrowia, 23 April,,17592,6.html [15 June 2010].

Related content

Powered by UNSILO

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

  • Piotr Ozierański (a1), Martin McKee (a2) and Lawrence King (a3)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.